Get the Stockscreener App
0.5434
2.98%
-0.0167
After Hours:
.52
-0.0234
-4.31%
Generation Bio Co stock is traded at $0.5434, with a volume of 275.54K.
It is down -2.98% in the last 24 hours and down -17.25% over the past month.
Generation Bio Co is a genetics medicine company that is focused on creating gene therapies to provide durable and redosable treatments for patients suffering from rare and untreated diseases. The company focuses on liver and retina-related diseases. It is developing two distinct and complementary platforms that It believes will enable highly differentiated therapeutic applications. Its first platform is a potent, highly selective ctLNP delivery system for nucleic acids, which is designed to avoid off-target clearance by the liver and spleen, enabling ctLNPs to persist in systemic circulation and allowing for highly selective and potent ligand-driven targeting to specific tissues and cell types. Its second platform is its novel iqDNA, which is an optimized variant of its ceDNA.
See More
Previous Close:
$0.5601
Open:
$0.58
24h Volume:
275.54K
Relative Volume:
0.54
Market Cap:
$36.41M
Revenue:
-
Net Income/Loss:
$-126.61M
P/E Ratio:
-0.2772
EPS:
-1.96
Net Cash Flow:
$-60.14M
1W Performance:
+3.50%
1M Performance:
-17.25%
6M Performance:
-81.00%
1Y Performance:
-81.70%
1-Day Range:
$0.5308
$0.5866
1-Week Range:
$0.4704
$0.5913
52-Week Range:
$0.4704
$4.65
Generation Bio Co Stock (GBIO) Company Profile
Name
Generation Bio Co
Sector
Industry
Phone
857-529-5908
Address
301 BINNEY STREET, CAMBRIDGE
Compare GBIO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GBIO
Generation Bio Co
|
0.5434 | 36.41M | 0 | -126.61M | -60.14M | -1.96 |
|
VRTX
Vertex Pharmaceuticals Inc
|
512.52 | 131.61B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
672.36 | 73.51B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
619.97 | 37.67B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
253.44 | 32.81B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
266.26 | 28.62B | 3.81B | -644.79M | -669.77M | -6.24 |
Generation Bio Co Stock (GBIO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-19-23 | Downgrade | TD Cowen | Outperform → Market Perform |
| Nov-08-22 | Initiated | Canaccord Genuity | Buy |
| Dec-14-21 | Downgrade | William Blair | Outperform → Mkt Perform |
| Jun-08-21 | Initiated | JMP Securities | Mkt Outperform |
| Feb-24-21 | Initiated | William Blair | Outperform |
| Feb-18-21 | Initiated | Needham | Buy |
| Jul-07-20 | Initiated | Cowen | Outperform |
| Jul-07-20 | Initiated | JP Morgan | Overweight |
| Jul-07-20 | Initiated | Jefferies | Buy |
| Jul-07-20 | Initiated | Wedbush | Outperform |
View All
Generation Bio Co Stock (GBIO) Latest News
Generation Bio’s (GBIO) Buy Rating Reaffirmed at Canaccord Genuity Group - Defense World
Generation Bio stock hits 52-week low at $0.47 - Investing.com
Generation Bio stock hits 52-week low at $0.47 By Investing.com - Investing.com South Africa
Generation Bio’s SWOT analysis: stock pivots to T-cell focus amid market caution By Investing.com - Investing.com South Africa
Generation Bio’s SWOT analysis: stock pivots to T-cell focus amid market caution - Investing.com India
Generation Bio’s (GBIO) Outperform Rating Reiterated at Wedbush - Defense World
Generation Bio Co. (NASDAQ:GBIO) Not Doing Enough For Some Investors As Its Shares Slump 29% - Simply Wall St
Generation Bio Co. Advances in Autoimmune Therapeutics - TipRanks
Generation Bio Co reports results for the quarter ended December 31Earnings Summary - TradingView
Generation Bio stock holds Market Perform rating at JMP - Investing.com India
Generation Bio stock holds Market Perform rating at JMP By Investing.com - Investing.com UK
Layoff Tracker: GRO Biosciences Cuts Staff Amid Quest for Strategic Alternatives - BioSpace
Generation Bio earnings missed by $0.02, revenue topped estimates - Investing.com South Africa
Generation Bio Co (GBIO) Q4 2024 Earnings: EPS Misses Estimate o - GuruFocus.com
Generation Bio Co. (GBIO) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance
Generation Bio Reports Business Highlights and Fourth Quarter and Full Year 2024 Financial Results - The Manila Times
Generation Bio Co. Advances T Cell-Selective siRNA Therapeutics for Autoimmune Diseases, Announces Robust Financial Position - Nasdaq
Generation Bio's Breakthrough: 98% T Cell Success Powers $185M Cash Runway Through 2027 - StockTitan
Generation Bio Co (GBIO)’s stock rises to 0.52 per share - US Post News
A Guide To The Risks Of Investing In Generation Bio Co (GBIO) - Knox Daily
Generation Bio stock hits 52-week low at $0.52 - Investing.com
Generation Bio stock hits 52-week low at $0.52 By Investing.com - Investing.com UK
Generation Bio (GBIO) Expected to Announce Quarterly Earnings on Wednesday - Defense World
Contrasting Generation Bio (NASDAQ:GBIO) & Anthera Pharmaceuticals (OTCMKTS:ANTH) - Defense World
Generation Bio faces Nasdaq delisting over share price By Investing.com - Investing.com Canada
Generation Bio faces Nasdaq delisting over share price - Investing.com India
Generation Bio to Present at the TD Cowen 45th Annual Health Care Conference - The Manila Times
Can Generation Bio's Autoimmune Disease Strategy Transform T Cell Treatment? CEO Reveals Plans - StockTitan
Kineticos Launches Kinvard Bio to Advance Next-Generation Antibiotics in the Fight Against Antimicrobial Resistance - PR Newswire
Generation Bio stock hits 52-week low at $0.6 amid sharp decline - Investing.com Nigeria
Generation Bio stock hits 52-week low at $0.6 amid sharp decline By Investing.com - Investing.com South Africa
Spore.Bio raises €22 million to deploy a new generation of AI-based microbiology testing - EU-Startups
Generation Bio stock hits 52-week low at $0.66 By Investing.com - Investing.com Nigeria
Generation Bio stock hits 52-week low at $0.66 - MSN
Insider Buying: Quinn Anthony G., Generation Bio Co [GBIO] Director invested 125,791 shares - Knox Daily
BBAI Stock Sees Surge of Approximately 95.33% in Last Five Days - Knox Daily
Insider Selling: Les Jason, Riot Platforms Inc [RIOT] CHIEF EXECUTIVE OFFICER divested 50,000 shares - Knox Daily
Biotech Executive Powerhouse: Ex-Generation Bio CFO Takes Dual Leadership Role at Rising ADC Developer Tubulis - StockTitan
Pioneering the next generation of bio-based polymers in partnership with London-listed Synthomer - University of York
Ratio Revelations: Generation Bio Co (GBIO)’s Financial Metrics in the Spotlight - The Dwinnex
Generation Bio (GBIO) Stock Price, News & Analysis - MarketBeat
Generation Bio Co Stock (GBIO) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):